Elias Sayour
Assistant Professor/M.D. | University of Florida
Gainesville, FL, UNITED STATES
Dr. Elias Saymour is an expert in pediatric oncology and hematology with a specialization in immunologic treatment of cancer.
Biography
Dr. Elias Sayour is the principal investigator of the RNA Engineering Laboratory within the Preston A. Wells, Jr. Center for Brain Tumor Therapy and UF Brain Tumor Immunotherapy Program. He is working to develop lipid-nanoparticles to train the immune system to fight cancer. Dr. Sayour's specialty is pediatric hematology-oncology.
Areas of Expertise (4)
Pediatric Oncology
mRNA Vaccines
Cancer Immunotherapy
Pediatric Cancer
Articles (3)
The current landscape of immunotherapy for pediatric brain tumors
Nature CancerEugene I. Hwang, et al.
2022-01-20
Pediatric central nervous system tumors are the most common solid malignancies in childhood, and aggressive therapy often leads to long-term sequelae in survivors, making these tumors challenging to treat. Immunotherapy has revolutionized prospects for many cancer types in adults, but the intrinsic complexity of treating pediatric patients and the scarcity of clinical studies of children to inform effective approaches have hampered the development of effective immunotherapies in pediatric settings.
Optimizing T Cell-Based Therapy for Glioblastoma
Frontiers in immunologyAida Karachi, et al.
2021-08-05
Evading T cell surveillance is a hallmark of cancer. Patients with solid tissue malignancy, such as glioblastoma (GBM), have multiple forms of immune dysfunction, including defective T cell function. T cell dysfunction is exacerbated by standard treatment strategies such as steroids, chemotherapy, and radiation. Reinvigoration of T cell responses can be achieved by utilizing adoptively transferred T cells, including CAR T cells.
Contemporary RNA Therapeutics for Glioblastoma
Neuromolecular medicineKaitlyn Melnick, et al.
2021-06-08
Glioblastoma (GBM) is the most common primary brain tumor in adults and is universally lethal with a median survival of less than two years with standard therapy. RNA-based immunotherapies have significant potential to establish a durable treatment response for malignant brain tumors including GBM. RNA offers clear advantages over antigen-focused approaches but cannot often be directly administered due to biological instability.
